Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Surlorian (ARM210, S48168) in Adults With Autosomal Dominant RYR1-Related Myopathy

NCT07560020 is registered in ClinicalTrials.gov with RyCarma Therapeutics, Inc. as lead sponsor.

NCT NCT07560020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07560020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Surlorian (ARM210, S48168) in Adults With Autosomal Dominant RYR1-Related Myopathy
Lead sponsor
RyCarma Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 9, 2026
Completion date
August 27, 2028
Enrollment
28 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant ryr1-related myopathy